Opinion on  ScheringPlough Corp (SGP)     Sector: Healthcare  >  Industry: Major Drugs
Schering-Plough Corp.

Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide. It operates in three segments: Human Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. Human Prescription Pharmaceuticals segment offers human pharmaceutical products in six therapeutic areas, including cardiovascular, central nervous system, immunology and infectious disease, oncology, respiratory, and women’s health. This segment sells its products through sales representatives to hospitals, managed care organizations, wholesale distributors, and retail pharmacists. Animal Health segment discovers, develops, manufactures, and markets animal health products, including vaccines. Its products include livestock products, poultry products, companion animal products, and aquaculture products. This segment offers its products to veterinarians, distributors, and animal producers. Consumer Health Care segment manufactures and sells over-the-counter, foot care, and sun care products. This segment sells its products through wholesale and retail drug, food chain, and mass merchandiser outlets. The company has a joint venture with Merck & Co., Inc. for the development and management of two cholesterol-lowering drugs and an allergy/asthma drug. Schering-Plough Corporation was founded in 1928 and is headquartered in Kenilworth, New Jersey.

What The Brokers Say

Trades for 19-Jun-2008

Time	Volume / Share Price
12:45	6 @ $19.20  ( blue colour )
12:45	2 @ $19.20  ( red colour )
12:45	5 @ $19.20  ( green colour )
12:45	1 @ $19.20  ( green colour )
12:45	150 @ $19.20  ( green colour )

On 6/9/09, SNTS announced that Schering-Plough (NYSE:SGP) HealthCare Products, Inc. has submitted its response to the FDA complete response letter (CRL) for an over-the-counter (OTC) Zegerid branded omeprazole/sodium bicarbonate product with the dosage strength of 20 mg of omeprazole. Schering-Plough received the complete response letter in January 2009 for its New Drug Application (NDA) seeking approval to sell Zegerid in the U.S. OTC heartburn market. The NDA for OTC Zegerid was submitted by Schering-Plough in March 2008 under the terms of a license agreement signed in October 2006 for OTC proton pump inhibitor products using Santarus' proprietary technology. If Schering-Plough receives FDA approval of its NDA for an OTC Zegerid product, SNTS will earn a $20 million regulatory milestone.